During the last session, Perspective Therapeutics Inc (AMEX:CATX)’s traded shares were 0.48 million, with the beta value of the company hitting 1.47. At the end of the trading day, the stock’s price was $12.09, reflecting an intraday gain of 2.37% or $0.28. The 52-week high for the CATX share is $19.05, that puts it down -57.57 from that peak though still a striking 81.8% gain since the share price plummeted to a 52-week low of $2.20. The company’s market capitalization is $815.20M, and the average intraday trading volume over the past 10 days was 0.52 million shares, and the average trade volume was 857.74K shares over the past three months.

Perspective Therapeutics Inc (CATX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. CATX has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.21.

Perspective Therapeutics Inc (AMEX:CATX) trade information

Perspective Therapeutics Inc (CATX) registered a 2.37% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 2.37% in intraday trading to $12.09, hitting a weekly high. The stock’s 5-day price performance is 4.86%, and it has moved by -8.48% in 30 days. Based on these gigs, the overall price performance for the year is 359.70%. The short interest in Perspective Therapeutics Inc (AMEX:CATX) is 7.88 million shares and it means that shorts have 6.4 day(s) to cover.

The consensus price target of analysts on Wall Street is $21, which implies an increase of 42.43% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3 and $24 respectively. As a result, CATX is trading at a discount of -98.51% off the target high and 75.19% off the low.

Perspective Therapeutics Inc (CATX) estimates and forecasts

Statistics show that Perspective Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Perspective Therapeutics Inc (CATX) shares have gone down -33.20% during the last six months, with a year-to-date growth rate more than the industry average at 37.86% against 18.10. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 47.50% this quarter and then jump 72.70% in the quarter after that. In the rating firms’ projections, revenue will decrease -85.90% compared to the previous financial year.

As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 170k as predicted by 8 analyst(s). Meanwhile, a consensus of 8 analyst(s) estimates revenue growth to 180k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 2.19M and 2.03M respectively. In this case, analysts expect current quarter sales to shrink by -92.20% and then drop by -91.20% in the coming quarter.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -7.69%. While earnings are projected to return 46.36% in 2024.

CATX Dividends

Perspective Therapeutics Inc is due to release its next quarterly earnings on 2024-Aug-12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Perspective Therapeutics Inc (AMEX:CATX)’s Major holders

Perspective Therapeutics Inc insiders own 20.43% of total outstanding shares while institutional holders control 62.15%, with the float percentage being 78.10%.